Journal
IMMUNOTHERAPY
Volume 10, Issue 10, Pages 827-830Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2017-0192
Keywords
cytokine-induced killer cell; immunotherapy; multidrug-resistant TB
Categories
Funding
- Science and Technology Plan of Jiangsu, China [BK20161230]
Ask authors/readers for more resources
In this report, we identified a multidrug-resistant tuberculosis (MDR-TB) patient who remained acid-fast bacilli culture positive despite aggressive WHO-directed therapy. Between July 2014 and February 2015, she received eight courses of cytokine-induced killer (CIK) cell-based adoptive cellular immunotherapy in combination to the second-line anti-TB treatment. This case achieved culture conversion, and experienced no relapse during 2-year follow-up under the treatment with CIK cell-based adoptive cellular immunotherapy. Our data indicate that CIK immunotherapy is a promising adjunctive therapeutic method for improving the efficacy combined with the second-line anti-TB regimens against MDR-TB. Randomized trials are warranted to confirm the efficacy and safety of adjunctive CIK therapy in patients infected with MDR-TB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available